Evidence map›Paper›PMID 27067260›Full record

ArticleScientific reports2016

C/EBPβ-Thr217 Phosphorylation Stimulates Macrophage Inflammasome Activation and Liver Injury.

Martina Buck, Jose Solis-Herruzo, Mario Chojkier

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05361733 (A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of XFB19 in Healthy Adult Volunteers.), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05361733 phase1recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of XFB19 in Healthy Adult Volunteers.

TypeinterventionalSponsorXfibra, Inc.Ran2026 to 2026Enrolled40ConditionsFocus of the Study: Safety of XFB19ArmsXFB19, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Martina BuckDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jose Solis-HerruzoDepartment of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Mario ChojkierDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Universidad Complutense de Madrid · ESUniversity of California, San Diego · USVA San Diego Healthcare System · US

Funding

HEPATOCYTE CONNECTIVE TISSUE PROTEIN PRODUCTION IN VIVOR01DK038652 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI CHOJKIER, MARIO · 1987 to 2009
$2.7M
Hepatitis C: E2 Molecular MechanismsR01DK084139 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI BUCK, MARTINA · 2010 to 2014
$1.6M
C/EBP beta Peptides for the Treatment of Hepatic FibrosisRC1DK087031 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI BUCK, MARTINA, CHOJKIER, MARIO · 2009 to 2010
$877k
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMSK01CA096932 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BUCK, MARTINA · 2002 to 2006
$675k
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung FibrosisR41HL127919 · NHLBI · XFIBRA, INC. · PI BUCK, MARTINA, CHOJKIER, MARIO · 2015 to 2015
$316k
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSISR41HL122022 · NHLBI · XFIBRA, INC. · PI BUCK, MARTINA, CHOJKIER, MARIO · 2014 to 2014
$312k
NCI NIH HHS K01 CA096932NCI NIH HHS K-22-CA-96932NHLBI NIH HHS R41 HL122022NHLBI NIH HHS R41 HL127919NIDDK NIH HHS R01 DK038652NIDDK NIH HHS R01 DK084139NIDDK NIH HHS R01-DK-38652NIDDK NIH HHS R01-DK-84139NIDDK NIH HHS R37-DK-46071NIDDK NIH HHS RC1 DK087031NIDDK NIH HHS RC1-DK-87031
6 · The paper itself

Abstract

Amplification of liver injury is mediated by macrophages but the signaling by which the macrophage inflammasome enhances liver injury is not completely understood. The CCAAT/Enhancer Binding Protein-β (C/EBPβ) is a critical signaling molecule for macrophages because expression of a dominant inhibitor of C/EBPβ DNA-binding sites or a targeted deletion of C/EBPβ results in impaired macrophage differentiation. We reported that expression of the phosphorylation-mutant C/EBPβ-Glu217, which mimics phosphorylated C/EBPβ-Thr217, was sufficient to confer macrophage survival to Anthrax lethal toxin. Here, using primary hepatocytes, primary liver macrophages, dominant positive and negative transgenic mice of the C/EBPβ-Thr217 phosphoacceptor, macrophage ablation, and an inhibitory peptide of C/EBPβ-Thr217 phosphorylation, we determined that this phosphorylation is essential for the activation of the inflammasome in liver macrophages and for the hepatocyte apoptosis induced by hepatotoxins that results in liver injury. Similar findings were observed in the livers of patients with acute injury induced by Toxic Oil Syndrome.

Indexed as

Protein Processing, Post-TranslationalAnimalsApoptosisCCAAT-Enhancer-Binding Protein-betaCells, CulturedHepatocytesHumansInflammasomesLiverMacrophagesMice, TransgenicPhosphorylationCCAAT-Enhancer-Binding Protein-betaInflammasomes

Identifiers

PMID27067260
PMCPMC4828658
OpenAlexW2336817505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.